Fujifilm has announced plans to buy U.S.-based drugmaker Biogen's biologics unit for approximately $890 million. According to the Japanese company the acquisition is meant to shore up its healthcare business.
The unit includes biologics manufacturing operations in Hillerød, Denmark and about 800 employees, which will continue working under Fujifilm. The operations contain bioreactors that can produce blockbuster drugs or biosimilars that need mass production.
Last year the Fujifilm said it would buy two biotechnology units from JXTG Holdings Inc for about $800 million.
According to Fujifilm, it expects this transaction to be completed in August.
This latest unit is Fujifilm's fourth and will still produce drugs for Biogen after the deal.
Read the full release.